- Published at
- by manilatimes.net
mixed
mixed
News for Oxford Biomedica plc (OXBDF)
- Published at
- by gurufocus.com
positivepositiveOxford BioMedica PLC (OXBDF) (Q2 2024) Earnings Call Transcript Highlights: Strong Revenue Growth and Strategic Advancements
Revenue: GBP50.8 million, up 18% from GBP43.1 million in the same period last year.Organic Revenue Growth: 38% excluding the impact of the acquisition of OXB F- Published at
- by gurufocus.com
positivepositiveHalf Year 2024 Oxford Biomedica PLC Earnings Call Transcript
Sep 23, 2024 / 12:30PM GMTFrank Mathias - Oxford Biomedica PLC - Chief Executive Officer, Executive Director Good afternoon, everyone and good morning to those- Published at
- by seekingalpha.com
neutralneutralOxford Biomedica plc (OXBDF) Q2 2024 Earnings Call Transcript
Oxford Biomedica plc (OTCPK:OXBDF) Q2 2024 Earnings Conference Call September 23, 2024 8:00 AM ETCompany ParticipantsFrank Mathias - Chief Executive...- Published at
- by investing.com
mixedmixed- Published at
- by globenewswire.com
mixedmixedInterim Results for the Six Months Ended 30 June 2024
Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of...- Published at
- by globenewswire.com
mixedmixedLucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford...- Published at
- by globenewswire.com
positivepositiveOxford Biomedica to host a free webinar showcasing its AAV expertise
Oxford Biomedica to host a free webinar showcasing its AAV expertise Oxford, UK - 27 August 2024: On Wednesday 11 September 2024, Oxford Biomedica, a...- Published at
- by globenewswire.com
positivepositiveOxford Biomedica – Half Year Trading Update and Notice of Interim Results
Half Year Trading Update and Notice of Interim Results Full year 2024 revenue and medium-term financial guidance reiterated; underpinned by OXB’s growing...- Published at
- by globenewswire.com
mixedmixedRetinal Gene Therapy market is projected to grow at a CAGR of 9.6% by 2034: Visiongain
Visiongain has published a new report entitled Retinal Gene Therapy Market Report 2024-2034: Forecasts by Approach (Gene Replacement, Gene Silencing, Gene...- Published at
- by marketscreener.com
mixedmixedEARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake -March 20, 2024 at 12:20 pm EDT
The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: ---------- Roadside Real Estate PLC -...- Published at
- by globenewswire.com
mixedmixedHomology Medicines Declares Distribution to Common Stockholders
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common...- Published at
- by globenewswire.com
mixedmixedGlobal Gene Therapy Market Size to Worth USD 49.21 Billion by 2032 | CAGR of 20.46%
The Global Gene Therapy Market Size was valued at USD 7.65 Billion in 2022 and the Worldwide Gene Therapy Market Size is expected to reach USD 49.21...- Published at
- by marketscreener.com
mixedmixedRecord down as managed assets decline
The following stocks are the leading risers and fallers among London Main Market small-caps on Friday. ---------- SMALL-CAP - WINNERS ---------- Regional REIT Ltd, up 4.4% at 27.52 pence, 12-month...- Published at
- by globenewswire.com
mixedmixedCell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 – Comprehensive Study by The Insight Partners
Global cell and gene therapy manufacturing services market is growing at a CAGR of 17.1% during 2022–2030....- Published at
- by marketscreener.com
positivepositiveAshley sells put options for million Frasers shares
The following is a round-up of share dealings by London-listed company directors and managers announced this week and not separately reported by Alliance News: ---------- Frasers Group PLC -...- Published at
- by marketscreener.com
mixedmixedMidatech Pharma : Biodexa Pharmaceuticals PLC?Annual Report 2022Biodexa Pharmaceuticals PLC(formerly Midatech Pharma Plc)Annual Report 2022 - Form 6-K
Biodexa Pharmaceuticals PLC?Annual Report 2022Biodexa Pharmaceuticals PLCAnnual Report 2022 ... | June 1, 2023- Published at
- by marketscreener.com
mixedmixedSUMMARY: London listings with exposure to Silicon Valley Bank
The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News: ---------- FTSE... | March 13, 2023- Published at
- by prnewswire.com
mixedmixedGlobal Engineered T Cells Market Report 2022-2027: Immuno-Oncology Sector Increasing R&D Funding & Expanding Gene Therapy Marketspace Generating High-Potential Opportunities
/PRNewswire/ --The "Global Engineered T Cells Market (2022-2027) by Type, Application, End User, Geography, Competitive Analysis and the Impact of Covid-19...- Published at
- by etfdailynews.com
mixedmixedEquities Research Analysts’ Upgrades for May 27th (AAWW, AN, ATDRY, ATO, AUTO, BOOT, BSX, DML, DNN, DXC)
Read Equities Research Analysts’ Upgrades for May 27th (AAWW, AN, ATDRY, ATO, AUTO, BOOT, BSX, DML, DNN, DXC) at ETF Daily News